These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 394479)

  • 1. Adriamycin (doxorubicin) cardiotoxicity: a review.
    Chlebowski RT
    West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible doxorubicin-induced congestive heart failure.
    Cohen M; Kronzon I; Lebowitz A
    Arch Intern Med; 1982 Aug; 142(8):1570-1. PubMed ID: 7103641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
    Swain SM; Whaley FS; Ewer MS
    Cancer; 2003 Jun; 97(11):2869-79. PubMed ID: 12767102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
    Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
    Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is the use of adriamycin (doxorubicin) limited by its cardiotoxicity?].
    Reinhardt D; Hofmann V; Martz G
    Schweiz Med Wochenschr; 1985 Apr; 115(16):557-61. PubMed ID: 4001904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
    Chlebowski RT; Paroly WS; Pugh RP; Hueser J; Jacobs EM; Pajak TF; Bateman JR
    Cancer Treat Rep; 1980 Jan; 64(1):47-51. PubMed ID: 7379058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive monitoring of adriamycin cardiotoxicity by "Sphygmo-Recording" of the pulse wave delay (QKd interval).
    Greco FA; Brereton HD; Rodbard D
    Cancer Treat Rep; 1976 Sep; 60(9):1239-45. PubMed ID: 797446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Echocardiography with angiotensin administration in the diagnosis of adriamycin-induced cardiomyopathy].
    Göldel N; Autenrieth G; Werdan K; Knesewitsch P; Wilmanns W
    Z Kardiol; 1989 May; 78(5):320-7. PubMed ID: 2735093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of doxorubicin-induced congestive heart failure by continuous intravenous infusion in multiple myeloma; a case report and review of the literature.
    Lieverse RJ; Ossenkoppele GJ
    Neth J Med; 1991 Feb; 38(1-2):33-4. PubMed ID: 2030807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
    J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adriamycin and mitomycin C: possible synergistic cardiotoxicity.
    Buzdar AU; Legha SS; Tashima CK; Hortobagyi GN; Yap HY; Krutchik AN; Luna MA; Blumenschein GR
    Cancer Treat Rep; 1978 Jul; 62(7):1005-8. PubMed ID: 688243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined cardiotoxicity of adriamycin and x-radiation.
    Fajardo LF; Eltringham JR; Steward JR
    Lab Invest; 1976 Jan; 34(1):86-96. PubMed ID: 1246126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
    Gershanovich ML; Moiceenko VM; Orlova RV
    Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation.
    Billingham ME; Bristow MR; Glatstein E; Mason JW; Masek MA; Daniels JR
    Am J Surg Pathol; 1977 Mar; 1(1):17-23. PubMed ID: 602969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis of adriamycin myocardiopathy using echocardiography].
    Harpf H; Lehnert M; Tschech G
    Acta Med Austriaca Suppl; 1979; 6():341-3. PubMed ID: 299226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
    Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
    N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin cardiomyopathy--risk factors.
    Minow RA; Benjamin RS; Lee ET; Gottlieb JA
    Cancer; 1977 Apr; 39(4):1397-402. PubMed ID: 856438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug-induced myocardial disease--adriamycin cardiotoxicity].
    Wakasugi S
    Nihon Rinsho; 2000 Jan; 58(1):204-11. PubMed ID: 10885315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.